Company Description

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease.

The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development.

The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.

The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

IGC Pharma, Inc.

Country	United States
Founded	2005
Industry	Biotechnology
Sector	Healthcare
Employees	67
CEO	Ram Mukunda

Contact Details

Address: 10224 Falls Road Potomac, Maryland 20854 United States
Phone	301 983 0998
Website	igcpharma.com

Stock Details

Ticker Symbol	IGC
Exchange	NYSEAMERICAN
Fiscal Year	April - March
Reporting Currency	USD
CIK Code	0001326205
CUSIP Number	45408X308
ISIN Number	US45408X3089
Employer ID	20-2760393
SIC Code	2834

Key Executives

Name	Position
Ram Mukunda	President, Chief Executive Officer and Director
Claudia Grimaldi	Vice President, Principal Financial Officer, Chief Compliance Officer and Non-Independent Director
Benysh Qureshi Esq., M.B.A.	Director of Operations
Rohit Goel	Senior Director of Accounting and Principal Accounting Officer

Latest SEC Filings

Date	Type	Title
Nov 12, 2024	10-Q	Quarterly Report
Sep 27, 2024	8-K	Current Report
Aug 27, 2024	8-K	Current Report
Aug 14, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership
Aug 9, 2024	144	Filing
Aug 7, 2024	10-Q	Quarterly Report
Aug 7, 2024	UPLOAD	Filing
Aug 2, 2024	8-K	Current Report
Jul 9, 2024	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 8, 2024	DEF 14A	Other definitive proxy statements

View All SEC Filings